Literature DB >> 8843294

Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.

A D Kashuba1, C H Ballow, A Forrest.   

Abstract

Data were gathered during an activity-controlled trial in which seriously ill, elderly patients were randomized to receive intravenous ceftazidime or ciprofloxacin and for which adaptive feedback control of drug concentrations in plasma and activity profiles was prospectively performed. The adaptive feedback control algorithm for ceftazidime used an initial population model, a maximum a posteriori (MAP)-Bayesian pharmacokinetic parameter value estimator, and an optimal, sparse sampling strategy for ceftazidime that had been derived from data in the literature obtained from volunteers. Iterative two-stage population pharmacokinetic analysis was performed to develop an unbiased MAP-Bayesian estimator and updated optimal, sparse sampling strategies. The final median values of the population parameters were follows: the volume of distribution of the central compartment was equal to 0.249 liter/kg, the volume of distribution of the peripheral compartment was equal to 0.173 liter/kg, the distributional clearance between the central and peripheral compartments was equal to 0.2251 liter/h/kg, the slope of the total clearance (CL) versus the creatinine clearance (CLCR) was equal to 0.000736 liter/h/kg of CL/1 ml/min/1.73 m2 of CLCR, and nonrenal clearance was equal to + 0.00527 liter/h/kg. Optimal sampling times were dependent on CLCR; for CLCR of > or = 30 ml/min/1.73 m2, the optimal sampling times were 0.583, 3.0, 7.0, and 16.0 h and, for CLCR of < 30 ml/min/1.73 m2, optimal sampling times were 0.583, 4.15, 11.5, and 24.0 h. The study demonstrates that because pharmacokinetic information from volunteers may often not be reflective of specialty populations such as critically ill elderly individuals, iterative two-stage population pharmacokinetic analysis, MAP-Bayesian parameter estimation, and optimal, sparse sampling strategy can be important tools in characterizing their pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843294      PMCID: PMC163430     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

2.  Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.

Authors:  J L Steimer; A Mallet; J L Golmard; J F Boisvieux
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

3.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

4.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

5.  Optimal sampling times for pharmacokinetic experiments.

Authors:  D Z D'Argenio
Journal:  J Pharmacokinet Biopharm       Date:  1981-12

6.  Pharmacokinetics of ceftazidime in patients with renal insufficiency.

Authors:  L S Welage; R W Schultz; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

Review 7.  Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime.

Authors:  L O Gentry
Journal:  Pharmacotherapy       Date:  1985 Sep-Oct       Impact factor: 4.705

8.  Determination of ceftazidime in biological fluids by using high-pressure liquid chromatography.

Authors:  C M Myers; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

9.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.

Authors:  C H O'Callaghan; P Acred; P B Harper; D M Ryan; S M Kirby; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

10.  Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers.

Authors:  G L Drusano; H C Standiford; B Fitzpatrick; J Leslie; P Tangtatsawasdi; P Ryan; B Tatem; M R Moody; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

View more
  4 in total

1.  Assessment of renal function in clinical practice at the bedside of burn patients.

Authors:  J M Conil; B Georges; O Fourcade; T Seguin; M Lavit; K Samii; G Houin; I Tack; S Saivin
Journal:  Br J Clin Pharmacol       Date:  2006-12-07       Impact factor: 4.335

2.  Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.

Authors:  Manjunath P Pai; Piergiorgio Cojutti; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

3.  Limited-sampling strategies for anti-infective agents: systematic review.

Authors:  Denise A Sprague; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2009-09

4.  Population pharmacokinetics of continuous infusion ceftazidime.

Authors:  B C Frame; B F Facca; D P Nicolau; S N Triesenberg
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.